- Dec 19, 2014
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
- Dec 18, 2014
Myeloma UK - Myeloma Animations Series: High Dose Therapy and Autologous Stem Cell Transplantation
- Dec 18, 2014
14th International Myeloma Workshop: April 3rd-7th, 2013 Kyoto, Japan
- Dec 18, 2014
Charlotte Radiology: Port Placement: Dr. Eric Wang
- Dec 17, 2014
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
- Dec 17, 2014
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
- Dec 16, 2014
NCT02064387: Phase 1 -Safety Pharm.kinetics Pharm.dynamics Img. & Cl. Activity GSK2857916 - DREAMM-1
- Dec 16, 2014
Myeloma UK - Myeloma Animations Series: Myeloma Kidney Disease
- Dec 14, 2014
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
- Dec 13, 2014
NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)
- Dec 13, 2014
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
- Dec 13, 2014
NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency
- Dec 12, 2014
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
- Dec 12, 2014
Khan Academy: What is a M-Spike? What is the difference b/w asymptomatic MGUS & symptomatic Myeloma
- Dec 12, 2014
Myeloma UK - Myeloma Animations Series: Myeloma - The Origin of the Myeloma Cell
- Dec 12, 2014
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
- Dec 12, 2014
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
- Dec 11, 2014
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
- Dec 11, 2014
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM